FGFR3-TACC3 fusion in solid tumors: Mini review

Oncotarget

Volumn 7, Issue 34, 2016, Pages 55924-55938

  Costa, Ricardo ^a   Carneiro, Benedito A ^a   Taxter, Timothy ^a   Tavora, Fabio A ^b   Kalyan, Aparna ^a   Pai, Sachin A ^a   Chae, Young Kwang ^a   Giles, Francis J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Robert H Lurie Comprehensive Cancer Center of Northwestern University ^*  (Brazil)

Author keywords

Aneuploidy; FGFR3 TACC3 fusion; Glioblastoma multiforme; Non small cell lung cancer; Phosphatidylinositol 3 Kinase (PI3K)

Indexed keywords

ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL TRIAL (TOPIC); ENDOMETRIUM CARCINOMA; FGFR3 TACC3 GENE; GALLBLADDER CARCINOMA; GENE FUSION; GENE TRANSLOCATION; GLIOMA; HUMAN; KIDNEY CARCINOMA; NON SMALL CELL LUNG CANCER; PANCREAS CARCINOMA; PREVALENCE; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CANCER; ANIMAL; GENETICS; NEOPLASM;

FGFR3 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MICROTUBULE ASSOCIATED PROTEIN; TACC3 PROTEIN, HUMAN;

ANIMALS; GENE FUSION; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TRANSLOCATION, GENETIC;

EID: 84983487456     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10482     Document Type: Article

References (42)

1. Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M and Giles FJ. Is Personalized Medicine Here? Oncology (Williston Park). 2016; 30:293-303, 307.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011; 364:2507-2516.
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine. 2010; 362:2380-2388.
4. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England journal of medicine. 2002; 347:472-480.
5. Touat M, Ileana E, Postel-Vinay S, Andre F and Soria JC. Targeting FGFR Signaling in Cancer. Clin Cancer Res. 2015; 21:2684-2694.
6. Gallo LH, Nelson KN, Meyer AN and Donoghue DJ. Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev. 2015; 26:425-449.
7. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J and Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4, 853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016; 22:259-67.
8. Lucia Nogova LVS, Philippe Alexandre Cassier, Manuel Hidalgo, Jean-Pierre Delord, Martin H. Schuler, Wan-Teck Lim, D. Ross Camidge, Reinhard Buettner, Lukas Carl Heukamp, Masyar Gardizi, Matthias Scheffler, Kato Kambartel, Francois Philippe Ringeisen, Suman Sen, et al. Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. J Clin Oncol. 2014; 32:5.
9. Lecia V. Sequist PC, Andrea Varga, Josep Tabernero, Jan HM Schellens, Jean-Pierre Delord, Patricia LoRusso, D. Ross Camidge, Manuel Hidalgo Medina, Martin Schuler, Mario Campone, G. Gary Tian, Steven Wong, Jesus Corral, et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA Philadelphia (PA): AACR; Cancer Res 2014;74:Abstract nr CT326 doi:101158/1538-7445AM2014-CT326.
10. Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, et al. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2015; 33:3401-3408.
11. Milind M. Javle RTS, Andrew Zhu, Saeed Sadeghi, SuPin Choo, Mitesh J. Borad, Maeve Aine Lowery, Anthony El-Khoueiry, Teresa Macarulla, Philip Agop Philip, Do-Youn Oh, Eric Van Cutsem, Kun-Huei Yeh, Randi Isaacs, Carolyn McGarry, Suman Sen, Tanios S. Bekaii-Saab. A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. J Clin Oncol. 2016; 34.
12. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer discovery. 2013; 3:636-647.
13. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (New York, NY). 2012; 337:1231-1235.
14. Stransky N, Cerami E, Schalm S, Kim JL and Lengauer C. The landscape of kinase fusions in cancer. Nature communications. 2014; 5:4846.
15. Williams SV, Hurst CD and Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Human molecular genetics. 2013; 22:795-803.
16. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T, Kosuge T and Shibata T. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014; 59:1427-1434.
17. Wang Y, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, et al. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer letters. 2016.
18. Huang ZL, Lin ZR, Xiao YR, Cao X, Zhu LC, Zeng MS, Zhong Q and Wen ZS. High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis. Oncotarget. 2015; 6:6850-6861. doi: 10.18632/oncotarget.3190.
19. Ha GH, Kim JL and Breuer EK. TACC3 is essential for EGF-mediated EMT in cervical cancer. PloS one. 2013; 8:e70353.
20. Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, Black JD and Still IH. Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health. 2005; 5:8.
21. Hood FE and Royle SJ. Pulling it together: The mitotic function of TACC3. Bioarchitecture. 2011; 1:105-109.
22. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, Yli-Harja O, Haapasalo H, Visakorpi T, Liu X, Liu CG, Sawaya R, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. The Journal of clinical investigation. 2013; 123:855-865.
23. Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, Savatovsky J, Touat M, Belaid H, Kamoun A, Idbaih A, Houillier C, et al. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. Clin Cancer Res. 2015; 21:3307-3317.
24. Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD and Craig DW. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016; 17:257-271.
25. Nelson KN, Meyer AN, Siari A, Campos AR, Motamedchaboki K and Donoghue DJ. Oncogenic Gene Fusion FGFR3-TACC3 is Regulated by Tyrosine Phosphorylation. Mol Cancer Res. 2016; 14:458-69.
26. Yuan L, Liu ZH, Lin ZR, Xu LH, Zhong Q and Zeng MS. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer biology & therapy. 2014; 15:1613-1621.
27. Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K, Ye WL, Hu BQ, Yan W, Zhang W, Akers J, Ramakrishnan V, Li J, Carter B, Liu YW, Hu HM, Wang Z, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome research. 2014; 24:1765-1773.
28. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507:315-322.
29. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, Yang Z, Li X, Song P, Zhao X, Ye R, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nature genetics. 2013; 45:1459-1463.
30. Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, Stephens PJ, Miller VA, Lindeman NI, Munir KJ, Richards WG and Janne PA. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res. 2014; 20:6551-6558.
31. Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, Pan Y, Ye T, Zhang Y, Luo X, Zhang Y, Pan B, Li B, Li H, Zhang J, Pao W, et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res. 2014; 20:4107-4114.
32. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014; 32:121-128.
33. Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJ, Brugman W, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. The Journal of pathology. 2013; 230:270-276.
34. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511:543-550.
35. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489:519-525.
36. Carneiro BA, Elvin JA, Kamath SD, Ali SM, Paintal AS, Restrepo A, Berry E, Giles FJ and Johnson ML. FGFR3-TACC3: A novel gene fusion in cervical cancer. Gynecologic oncology reports. 2015; 13:53-56.
37. Xiang L, Li J, Jiang W, Shen X, Yang W, Wu X and Yang H. Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. Oncotarget. 2015; 6:4968-4975. doi: 10.18632/oncotarget.3212.
38. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517:576-582.
39. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T and Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell cycle (Georgetown, Tex). 2015; 14:2121-2128.
40. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ and Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:3967-3972.
41. Sweis RF SS, Gajewski T. Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer. J Clin Oncol 2015;33:abstract 4511.
42. Spranger S, Bao R and Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015; 523:231-235